Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$5.05
-1.0%
$4.95
$1.62
$7.27
$450.16M-0.591.19 million shs1.38 million shs
Biohaven Ltd. stock logo
BHVN
Biohaven
$14.51
+0.8%
$17.90
$13.87
$55.70
$1.48B0.951.28 million shs2.79 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.29
$1.35
$1.19
$2.04
$1.02B1.393.87 million shs14.29 million shs
Xencor, Inc. stock logo
XNCR
Xencor
$8.54
+2.2%
$9.07
$7.16
$27.24
$607.79M0.87665,786 shs1.65 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
0.00%-8.51%-4.90%+33.60%+183.71%
Biohaven Ltd. stock logo
BHVN
Biohaven
0.00%-5.97%-7.43%-53.16%-56.78%
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.00%-3.01%+2.38%-28.73%+5.74%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%-7.07%+12.81%-34.05%-56.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.5737 of 5 stars
4.63.00.00.01.33.30.6
Biohaven Ltd. stock logo
BHVN
Biohaven
2.9754 of 5 stars
4.51.00.00.01.62.50.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.6066 of 5 stars
3.43.00.04.42.75.00.6
Xencor, Inc. stock logo
XNCR
Xencor
3.8768 of 5 stars
3.42.00.03.92.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.10
Buy$10.14100.85% Upside
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$58.46303.04% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75113.18% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00227.87% Upside

Current Analyst Ratings Breakdown

Latest AMLX, BHVN, XNCR, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.00
6/17/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
5/30/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
5/19/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.00
5/14/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.00
5/9/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $16.00
5/8/2025
Xencor, Inc. stock logo
XNCR
Xencor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.00
5/7/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.00
5/6/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$87.37M5.15N/AN/A$2.40 per share2.10
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.43$0.07 per share18.75$2.00 per share0.65
Xencor, Inc. stock logo
XNCR
Xencor
$110.49M5.50N/AN/A$9.63 per share0.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$301.74M-$3.11N/AN/AN/AN/A-77.21%-63.84%8/6/2025 (Estimated)
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)

Latest AMLX, BHVN, XNCR, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A
5/8/2025Q1 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.45-$0.42+$0.03-$0.42N/AN/A
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/AN/AN/AN/AN/A
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
12.05
12.05
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
2.33
2.33
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
11.70%
Biohaven Ltd. stock logo
BHVN
Biohaven
14.60%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Xencor, Inc. stock logo
XNCR
Xencor
5.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
20089.14 million78.71 millionOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239102.11 million87.21 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.45 millionOptionable

Recent News About These Companies

Xencor (NASDAQ:XNCR) Stock Price Down 5.7% on Insider Selling
Xencor Reports First Quarter 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$5.05 -0.05 (-0.98%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$5.06 +0.00 (+0.10%)
As of 06/20/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Biohaven stock logo

Biohaven NYSE:BHVN

$14.50 +0.12 (+0.80%)
Closing price 06/20/2025 03:59 PM Eastern
Extended Trading
$14.48 -0.03 (-0.21%)
As of 06/20/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.29 0.00 (0.00%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$1.30 +0.01 (+0.47%)
As of 06/20/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Xencor stock logo

Xencor NASDAQ:XNCR

$8.54 +0.18 (+2.15%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$8.52 -0.01 (-0.18%)
As of 06/20/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.